Dry powder inhalation in patients with Parkinson’s disease.
Completed
- Conditions
- Ability of a Parkinson’s patient to use the inhaler correctly during off periods.
- Registration Number
- NL-OMON24879
- Lead Sponsor
- Department of Pharmaceutical Technology and Biopharmacy, Faculty of Mathematics and Natural Sciences, University of Groningen
- Brief Summary
/A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 15
Inclusion Criteria
Predictable off periods.
Recognizable off periods for themselves and others.
Exclusion Criteria
Cognitive dysfunction, which precludes good understanding of instructions and/or informed consent.
Current treatment with apomorphine or duodopa by pump.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The parameter that describes whether or not a Parkinson’s patient is capable of using the inhaler correctly is the pressure drop (s)he creates over the inhaler upon inhalation.
- Secondary Outcome Measures
Name Time Method Peak and mean inspiratory flow rate (PIFR and MIFR).<br>Acceleration towards peak inspiratory flow rate (flow increase rate: FIR).<br>Inhaled volume.<br>Total inhalation time.<br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms enable dry powder inhalation to improve motor function in Parkinson’s disease patients during off periods?
How does dry powder inhalation compare to standard oral therapies in managing Parkinson’s motor fluctuations?
Which biomarkers correlate with successful inhaler use in Parkinson’s patients with dyskinesia or bradykinesia?
What are the potential adverse events associated with pulmonary drug delivery in Parkinson’s disease and how are they managed?
Are there synergistic effects when combining inhaled therapies with levodopa or MAO-B inhibitors in Parkinson’s treatment?